Entering text into the input field will update the search result below

Allena Pharma to file IND for ALLN-346 in H1 2019

Jun. 19, 2018 10:02 AM ETAllena Pharmaceuticals, Inc. (ALNAQ) StockBy: Douglas W. House, SA News Editor1 Comment
  • Allena Pharmaceuticals (NASDAQ:ALNA -0.6%) has completed an animal proof-of-concept study supporting the rationale for ALLN-346 for the treatment of hyperuricemia (excess uric acid in the blood) in gout patients with associated chronic kidney disease (CKD).
  • The preclinical results will be submitted for presentation at a scientific conference in H2. A U.S. IND, allowing the company to initiate early-stage studies if approved, is on tap for H1 2019.
  • ALLN-346 is an orally available non-absorbed urate-degrading enzyme designed to reduce the urate (ester of uric acid) burden on the kidney by degrading urate in the GI tract.
  • Gout-related tickers: (SELB -0.5%)(IRWD -1.3%)(CBAY -1.1%)(AZN -1.1%)

Recommended For You

About ALNAQ Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ALNAQ--
Allena Pharmaceuticals, Inc.